fluorobenzenes has been researched along with Infarction, Middle Cerebral Artery in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Wang, Z; Xing, H | 1 |
| Doerfler, A; Engelhorn, T; Heusch, G; Schulz, R | 1 |
| Ahn, YM; Byun, HY; Cho, JY; Cho, SI; Chung, JM; Gwag, BJ; Im, DS; Kim, KW; Ko, SY; Kwon, HJ; Lee, HU; Lee, JY; Lee, MJ; Lee, YA; Lim, HR; Moon, HS; Noh, JH; Park, SM; Son, SJ; Won, SJ; Yoon, SH; Yun, BS | 1 |
| Balkaya, M; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Leithner, C; Lindauer, U; Prinz, V | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Nickenig, G | 1 |
5 other study(ies) available for fluorobenzenes and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Topics: Animals; Blotting, Western; Brain Infarction; Brain Ischemia; Cell Count; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion; Rosuvastatin Calcium; Staining and Labeling; Sulfonamides; Time Factors | 2005 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebral Infarction; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Treatment Outcome | 2006 |
Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.
Topics: Animals; Antioxidants; Aspirin; Benzoates; Brain Ischemia; Cells, Cultured; Excitatory Amino Acid Antagonists; Fluorobenzenes; Infarction, Middle Cerebral Artery; meta-Aminobenzoates; Mice; N-Methylaspartate; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Salicylates; Sulfasalazine | 2007 |
Intravenous rosuvastatin for acute stroke treatment: an animal study.
Topics: Acute Disease; Animals; Aorta; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Injections, Intravenous; Mice; Mice, Inbred Strains; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Recovery of Function; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides | 2008 |
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred Strains; Neuroprotective Agents; Nitric Oxide Synthase; Pyrimidines; Reperfusion Injury; RNA, Messenger; Rosuvastatin Calcium; Stroke; Sulfonamides; Up-Regulation | 2002 |